We conducted a multicenter and open-label study with two parallel arms: a phase IIa study of PLX2853 monotherapy in patients with advanced gynecologic malignancies with an ARID1A mutation and a phase ...

Surveying mutations that may contribute to bladder cancer, Hsieh noticed that ARID1A is one of the most frequently mutated genes, suggesting that it usually works to suppress tumor formation in some ...

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable ...

An ARID1A gene-deficient human endometrial tumor being infiltrated by CD8+ T cells (yellow). All cell nuclei are colored blue, including tumor cells and CD8+ T cells. LA JOLLA (May 15, 2024 ...

When ARID1A is mutated, a microscopic chain of events analogous to a Rube Goldberg machine is set off in the cancer cell. First, the lack of functional ARID1A leads to escape of DNA into the cytosol.

Nuvectis Pharma announced that it has initiated a phase 1b study to assess a novel HSF1 pathway inhibitor for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

--Nuvectis Pharma, Inc. today announced preliminary data from the ongoing Phase 1 b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of ...

The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA, and Orphan Drug Designation for the treatment of ARID1a-deficient ...

AT-rich interactive domain-containing protein 1A (ARID1A) encodes a switch/sucrose nonfermentable (SWI/SNF) complex and is mutated in around 10% of colorectal cancers. ARID1A deficiency damages DNA ...

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell, 2024; DOI: 10.1016/j.cell.2024.04.025 ...